- direct tissue arteriole diameter measurements to assess vasoactivity
- comparing standard measurement of oxygen delivery to direct tissue oxygen concentrations
- determining if there are any effects of oxidative stress, inflammation and apoptosis
“We believe that Oxycyte has tremendous potential to provide therapeutic benefit for a number of acute ischemic conditions. All branches of the military are concerned with providing the best battlefield care possible. Demand is highest for therapies that buy more time for soldiers with traumatic injuries as they are transported from remote areas to hospitals and emergency medical units. We are pleased that the Navy has expanded its interest in Oxycyte as a potential therapeutic agent for the treatment of hemorrhagic shock for our sailors and soldiers suffering acute battlefield injuries,” said Michael Jebsen, President and Chief Financial Officer of Oxygen Biotherapeutics.About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte ® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte ® line of skin care cosmetics for the anti-aging market. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and Dermacyte product lines, the timing of the introduction of those new products, and the progress of our research programs, including preclinical and clinical testing. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.